ENPICOM
Investment to bolster international partnerships and advance AI-driven solutions for antibody discovery
‘s-Hertogenbosch, Netherlands – March 21, 2024 – ENPICOM, an innovative bioinformatics software solutions provider, has reached a major milestone by securing additional growth capital from its current investors, BOP Impact Ventures and BOM Brabant Ventures, aimed at expanding the development of ENPICOM’s AI assets. Furthermore, the company proudly welcomes Dr. Colby Souders, a seasoned expert in antibody discovery, to its group of investors. This infusion of growth capital not only underscores the unwavering confidence of existing investors in ENPICOM’s vision and technological prowess but also signifies a pivotal moment as the company embarks on an accelerated growth trajectory within the dynamic antibody discovery market.
“I am excited to collaborate with ENPICOM on their mission to empower lab and data scientists for maximum productivity,” said Colby Souders. “Their groundbreaking software, exceptional expertise, and rapidly expanding client portfolio, is truly impressive. I firmly believe that by harnessing cutting-edge technologies like AI and machine learning, we can empower scientists to innovate faster and drive transformative breakthroughs in therapeutic discovery.”
“We are honored to have BOP Impact Ventures, BOM Brabant Ventures, and Colby Souders, with his proven track record and unique insight into the challenges and opportunities within the drug discovery industry, share our mission and place their trust in our team,” expressed Paul van der Velde, CEO at ENPICOM. “With this robust backing and long-term investment horizon, we stand in a strong position to pioneer cutting-edge solutions that will revolutionize the discovery market.”
Holding a PhD in Cell and Molecular Biology from Texas A&M, Dr. Souders has held key positions at leading companies such as Twist Bioscience, Abveris, MassBiologics, and Kanyos Bio (now Anokion). In 2023, Dr. Souders joined BrickBio, Inc. as the Chief Scientific Officer.
The latest capital injection will empower ENPICOM to amplify its platform functionalities, further enriching its renowned IGX Platform and offering its clients and partners an unparalleled suite of BCR and TCR data analysis solutions. Moreover, ENPICOM will leverage its proprietary generative AI models to enhance and create developable therapeutic candidates, thereby increasing the quantity and quality of selected antibodies.
ENPICOM Media Contact
Svitlana Lozova
+31 85 250 0575
communications@enpicom.com
About ENPICOM
ENPICOM is an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health. With a diverse team of experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system to biotech and global pharmaceutical companies focusing on the discovery and development of novel antibodies and vaccines.
Leveraging a unique mix of immunology knowledge, bioinformatics methods, and software development skills, ENPICOM offers a world-class repertoire sequencing data analysis solution – the ImmunoGenomiX (IGX) Platform. IGX is an innovative platform to manage, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors. Moreover, together with its partners, ENPICOM also delivers full immune repertoire sequencing and analysis on demand. For additional information, please visit enpicom.com.